Market Overview

Verona Pharma Shares Up 22.5% Following Release of Data From Phase 2b Clinical Trial Of RPL554 Showing Treatment Met Primary Endpoint, Was Well Tolerated At All Dose Levels


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech News FDA Movers Trading Ideas General


Related Articles (VRNA)

This Day In Market History: OPEC Raises Crude Oil Prices By 9%

Gene Munster: After Facebook Fallout, Investors Could Flock To Privacy Safe Havens